Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 10/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598058 | 1.00 | HCRTR2 (0.49) | HCRTR2HCRTR1MEN1TSHRKMT2A | |
| SCHEMBL1598949 | 0.89 | HCRTR2 (0.61) | HCRTR2HCRTR1MEN1TSHRKMT2A | |
| SCHEMBL1598946 | 0.89 | HCRTR2 (0.61) | HCRTR2HCRTR1MEN1TSHRKMT2A | |
| SCHEMBL1598859 | 0.87 | TP53 (0.57) | HCRTR2HCRTR1MEN1TSHRKMT2A | |
| SCHEMBL1598863 | 0.87 | TP53 (0.57) | HCRTR2HCRTR1MEN1TSHRKMT2A | |
| SCHEMBL1597568 | 0.87 | MEN1 (0.49) | HCRTR2HCRTR1MEN1TSHRKMT2A | |
| SCHEMBL1597566 | 0.87 | MEN1 (0.49) | HCRTR2HCRTR1MEN1TSHRKMT2A | |
| SCHEMBL5139148 | 0.85 | TP53 (0.50) | HCRTR2HCRTR1TP53 | |
| SCHEMBL5139149 | 0.85 | TP53 (0.50) | HCRTR2HCRTR1TP53 | |
| SCHEMBL1597774 | 0.85 | HCRTR2 (0.48) | HCRTR2HCRTR1MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | claimed |
| EP-1385845-B1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2008-01-09 | — | — | EP | claimed |
| US-7919507-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| US-7741329-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1956020-A2 | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity | SMITHKLINE BEECHAM PLC (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1385845-B1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | HCRTR2 344/4885HCRTR1 417/4885MEN1 1089/4885 |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | HCRTR2 344/4885HCRTR1 417/4885MEN1 1089/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | HCRTR2 344/4885HCRTR1 417/4885MEN1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.